Aspirin Use and Respiratory Morbidity in COPD: A Propensity Score‐Matched Analysis in Subpopulations and Intermediate Outcome Measures in COPD Study

[1]  Meilan K. Han,et al.  Anemia and Adverse Outcomes in a Chronic Obstructive Pulmonary Disease Population with a High Burden of Comorbidities. An Analysis from SPIROMICS , 2018, Annals of the American Thoracic Society.

[2]  C. Camargo,et al.  The association of aspirin use with severity of acute exacerbation of chronic obstructive pulmonary disease: a retrospective cohort study , 2018, npj Primary Care Respiratory Medicine.

[3]  Eric A. Hoffman,et al.  A Longitudinal Cohort Study of Aspirin Use and Progression of Emphysema‐like Lung Characteristics on CT Imaging: The MESA Lung Study , 2017, Chest.

[4]  D. McAuley,et al.  Aspirin reduces lipopolysaccharide-induced pulmonary inflammation in human models of ARDS , 2017, Thorax.

[5]  David Couper,et al.  SPIROMICS Protocol for Multicenter Quantitative Computed Tomography to Phenotype the Lungs. , 2016, American journal of respiratory and critical care medicine.

[6]  R. Ferrari,et al.  Antiplatelet Treatment Reduces All-Cause Mortality in COPD Patients: A Systematic Review and Meta-Analysis , 2016, COPD.

[7]  V. Kim,et al.  Comparison between an alternative and the classic definition of chronic bronchitis in COPDGene. , 2015, Annals of the American Thoracic Society.

[8]  G. Campo,et al.  Relationship between Troponin Elevation, Cardiovascular History and Adverse Events in Patients with acute exacerbation of COPD , 2015, COPD.

[9]  Thierry Troosters,et al.  An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease , 2014, European Respiratory Journal.

[10]  Meilan K. Han,et al.  Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. , 2014, The New England journal of medicine.

[11]  P. Williamson,et al.  Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy? , 2014, Thorax.

[12]  S. Kon,et al.  Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. , 2014, The Lancet. Respiratory medicine.

[13]  C. Lazaridis,et al.  Analyzing propensity matched zero-inflated count outcomes in observational studies , 2014, Journal of applied statistics.

[14]  P. Poole,et al.  Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). , 2013, The Cochrane database of systematic reviews.

[15]  Lisa M LaVange,et al.  Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS) , 2013, Thorax.

[16]  V. Kim,et al.  Chronic bronchitis and chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.

[17]  M. Ekström,et al.  Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.

[18]  Courtney Crim,et al.  Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype , 2012, PloS one.

[19]  Steve Gupta.  Side-effects of roflumilast , 2012, The Lancet.

[20]  John Connett,et al.  Azithromycin for prevention of exacerbations of COPD. , 2011, The New England journal of medicine.

[21]  Brian J Lipworth,et al.  Effect of β blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study , 2011, BMJ : British Medical Journal.

[22]  A. Kaplan.  Effect of tiotropium on quality of life in COPD: a systematic review. , 2010, Primary care respiratory journal : journal of the General Practice Airways Group.

[23]  L. Fabbri,et al.  Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents , 2010, Respiratory research.

[24]  P. Austin,et al.  Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies , 2010, Pharmaceutical statistics.

[25]  Elizabeth A Stuart,et al.  Matching methods for causal inference: A review and a look forward. , 2010, Statistical science : a review journal of the Institute of Mathematical Statistics.

[26]  P. Jones,et al.  Development and first validation of the COPD Assessment Test , 2009, European Respiratory Journal.

[27]  D. Sin,et al.  The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. , 2008, American journal of respiratory and critical care medicine.

[28]  R. Rodríguez-Roisín,et al.  Safety of long-acting beta-agonists in stable COPD: a systematic review. , 2008, Chest.

[29]  Kevin J. Anstrom,et al.  Using Inverse Probability-Weighted Estimators in Comparative Effectiveness Analyses With Observational Databases , 2007, Medical care.

[30]  L. Fabbri,et al.  Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[31]  T. Omland,et al.  Statin use is associated with reduced mortality in COPD , 2006, European Respiratory Journal.

[32]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[33]  P. Jones.  St. George's Respiratory Questionnaire: MCID , 2005, COPD.

[34]  M. Ong,et al.  Breath carbon monoxide as an indication of smoking habit in the military setting. , 2004, Singapore medical journal.

[35]  N Rifai,et al.  Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. , 2001, JAMA.

[36]  A. Morice,et al.  Breath carbon monoxide as an indication of smoking habit. , 2000, Chest.

[37]  P. Nihoyannopoulos,et al.  Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. , 1999, Circulation.

[38]  ChristodoulosStefanadis,et al.  Increased Proinflammatory Cytokines in Patients With Chronic Stable Angina and Their Reduction By Aspirin , 1999 .

[39]  P. Jones,et al.  Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease , 1999, Thorax.

[40]  R. D'Agostino.  Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .

[41]  G. Davı̀,et al.  Enhanced thromboxane biosynthesis in patients with chronic obstructive pulmonary disease. The Chronic Obstructive Bronchitis and Haemostasis Study Group. , 1997, American journal of respiratory and critical care medicine.

[42]  P. Jones,et al.  A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. , 1992, The American review of respiratory disease.

[43]  C. Patrono,et al.  Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. , 1982, The Journal of clinical investigation.

[44]  J. Tallon,et al.  patients: a systematic review and meta-analysis related to prehospital recognition of agonal breathing and cardiac arrest , 2019 .

[45]  R. Rodríguez-Roisín,et al.  Safety of long-acting beta-agonists in stable COPD: a systematic review. , 2008, Chest.

[46]  Marcelo Coca-Perraillon.  Matching with Propensity Scores to Reduce Bias in Observational Studies , 2006 .

[47]  J. Wedzicha.  Role of viruses in exacerbations of chronic obstructive pulmonary disease. , 2004, Proceedings of the American Thoracic Society.